899.8000 -1.95 (-0.22%)
NSE Dec 05, 2025 15:31 PM
Volume: 62,002
 

899.80
-0.22%
Deven Choksey
We maintain a positive FY26E outlook, expecting sustained double-digit growth across US, Ex-US, and RoW businesses. Growth across regions will be majorly driven by a healthy US pipeline, strategic expansion in RoW, and improved execution across India.
Alembic Pharmaceuticals Ltd. is trading below all available SMAs
More from Alembic Pharmaceuticals Ltd.
Recommended